The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Ridaforolimus + Dalotuzumab|DRUG: Ridaforolimus|DRUG: Dalotuzumab
Sponsor: Merck Sharp & Dohme LLC